{"id":926684,"date":"2026-01-13T07:59:25","date_gmt":"2026-01-13T12:59:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/"},"modified":"2026-01-13T07:59:25","modified_gmt":"2026-01-13T12:59:25","slug":"ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/","title":{"rendered":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Jan.  13, 2026  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026.<\/p>\n<p>Study investigators leading the webcast include:<\/p>\n<ul type=\"disc\">\n<li>Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine<\/li>\n<li>Jay Chhablani, MD, Vitreo-Retina Specialist at the University of Pittsburgh Eye Center<\/li>\n<li>Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine<\/li>\n<\/ul>\n<p>Attendees are invited to participate on the call using the following details:<\/p>\n<p>\n        <strong>Dial-in Numbers:<\/strong> (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers<br \/><strong>Conference ID:<\/strong> 7783588<br \/><strong>Webcast:<\/strong> Available on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iAmFe_uN3UF355l4QpdG2H6n9Aw3ZFbICwIRzqiP68zS9geqv_X2l60Wh_WHfEPqs7riGJP5J3QAOVAt6E2m3xpnoI5a48x8NF0ni1Q6syGNprQMg3_mY_CdCHFgV_-mQyh3tuhZ3vpRUlyWASswrfTrDJs_kGXdpyEo2aQdBCDjW02GaxfPP1NyThz4gaZ9zpmudODn7JW2IYoACo0xO616z25RuLglpbE9tkyxb9mGHmPLMxdLKMx7qlpIK-vA5hOK9UwWsu4lgA3Ur6pIcm0DrGqNjEkKGfhcybF6jfySvfAqmEk_qCcbkBmYHBMMN4f-35tbnT2_ar_zjs2qjgx6s4iTw5P5bLqov61Ez17t2bvDJV8XHvrnbNSDKfmNVy-18CWLs-yYMcw9LKiAQg==\" rel=\"nofollow\" target=\"_blank\">events<\/a>\u00a0section of the Ocugen\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IENuqeL0Zlrfd9ghDpK3ZmObgt2c4ASTiAgXc7H2dAWrbZpq0_f47duYfCvKQq4TqFXpXyPzV9GnxeS_KarF-TiffPRcrktV5DaRL1Q7nff0VCBfGwuRC80yjW-33Rct9OQll-JUCnVh8mDu58aBiodnvhUIh-8_i-9U1VjBYGB6C7zzxlUMCByhGy8thHVIu_AYylE9IhbPPH7Wg7-MFeHzYlVCbA8k-zVZ2A9-bu9gFVqdsFuzuc2O2BiSMnu3f6mmLGeyDyPeVBvW-PZ_dZx00GWN_VrC1dtjbWyCT9bTvMbDaa8ySnR1q6VLiE0JZHbvPH8dkMpocPlRepFzeLFwqM9QpDRebt3-_QtdxoUrGeXrfKu3U8w9O2GTpnUJFv1mh_yP38pp7wIlN2mgP06698CikYrC70lcPg8J82k=\" rel=\"nofollow\" target=\"_blank\">investor site<\/a><\/p>\n<p>A replay of the call and archived webcast will be available following the event on the Ocugen\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IENuqeL0Zlrfd9ghDpK3ZmiykqMQMBSZ1vpmgJgcWYPYKTqh7gs5_2NYDdEnoCbOIcVgEJjL-SZoCXrb9-zdb5_IXErgJOMxLDZxVHsx7PSrSvo7sYT-izaM3GCBPdPRXFU3rYZq9yMmfIo7oG8NgSQvNvAtnpUntzqmrHXD178x9lpkalnE78hBwKEiEcxOot8xxiytHxr7YqZuzoDSJhd_KlxZWtGSMXQ3Gx1r9cLMmVixrW0eQgv8TdY2IvIX47Vq2SL_Be26fvK_d1c9_HNNwFO8d6qW0c-FBTmE2kHCGWqBj0jgDPEQgPmre9E4skT4k5yKUmHeX4l7i-VufSO7FrJoacJyUgBs1I6x_OdnMyfWn3WtVFwuhtY28HUnvYnaE8zQwJ-uD9SRS4mTNk4BJ6hHErgEhPiApy4bZ28=\" rel=\"nofollow\" target=\"_blank\">investor site<\/a>.<\/p>\n<p>\n        <strong>About Ocugen, Inc.<\/strong><br \/>\n        <br \/>Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen\u2019s modifier gene therapies address the entire disease\u2014complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy\u2014late stage dry age-related macular degeneration. Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1vthOtpE08OLcVt-vN81vKv6JjVN4iL-QvTZKUw1o4Bez3QkUXutI6jUYoEQgAkXYLpcBJI31gF1S4zxxMgOYVCQKWtKtAhyXiNhL-rEYV1N4Yg2SJbw1ws8JazzKtBJGUzZgOBpPuU0rjL1m44xwfVQZjpb9MGO4Hw_Fd6kgoNH1ocRYLqUtNYH8a0ZuH5WhQU1H47EsWrbgHB8Rdpp7KVsH1x0UpU781EeRI6v3ETn_p1MNI_9ss3S9K00ZXM-am_0meSW2f3SRgXgZ25apvpogl9y9OnwLGuMD26pfaMnbJnAT3uWhWlRv5T8b4oD91ct7-moKYq-JQWe9tQ4DejdJmEqRR-pmJA9yLI6F3sTdcbbNpCCTDP0_edmbGVjiQ8H9dRvQaFkjRROabs6-uul0vLxi6on4jla7IoVm4Zx0XFFve9PtaxeYy0IZwHjfbPBHAEcVkG02C3oGwYN0EmauPdjcv4Irx2euk-oRNIpwfr58dfthyp0v2sKPF_VwMdtL2qlTK7Ayc0nZBdDa9QP82FQZ2hR8WdbHknZ2d5lrn1SOv0bj4D19AemNC9RzD7zNV3Bf9i7m-CO4GHtGMeaUN_apXoF4CAtHWLF1RfVHmIow7G8x1gluaNIRHNR_1YrGKCLe5KdxJmW2s3t_A9-jeg1P11NCot5jBvO8IUtJ2XNy9YcCGuibZkfRRA84iEFofJB5S9uKKJT2GbIOH54xG3SkFpBL0gVH_6DeHM3DaWCAeaL1oZC6Ahv6BNPWtiO_wCA-pKBFNRpM6fG3lZOCqteLWInexDcjhVVkNNO_iG06M80FzDafQvUAv4zmTghQi_iGB1xLCiibsGW6Vm1VXVI1GTIOM3mEl5m2LOQwl4JZGpBNAZDcKC2rYaORxraZYpH8fbU75_YXNelg7VgR-cxKwkQ9zL_RECX61WIeiHCd7qZnpneKgBTXsqum_tjOeH5TS-bZDUmRxXGQDYix0CLzBNHPYK2YL32PQ2u61DwHv7YdleC2fjHwYrT\" rel=\"nofollow\" target=\"_blank\">www.ocugen.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L1sR2NV7fM7xzpINHo_jwHyYMSRNXwCopW9a6zzyByM4RtdOrSA_OSIO3ZTPR269qj5KdO_C4Eeox7wUIsxphD6BmdSXLtZrnEPrrzu2IL7vaaLxl1fGRNAFhwqPE2-W26N1qtdTj7u8NlUTSGYyfj4oMOzq_7EmRPN9HW_ccHxNSA6v9sXdguNsWNQKoFoduH6Cv3Q4OCodyeAahkNKOg0LyKHG_TVcJ7fj-Mhm7lyZu9QUCskCON__7oFWTXOlG2id2Ues7MqmeKi__uZKnNI3eOvorqtgI_RCbeoCBS-BbtPi1LDy87YE0jH7F63t6HjxbdXlF66_PVHsDb43cA7910lxOmvgTTxaX4j77UNt9_nU87J3_8CnBz48SHoXcMsgmW0Rxdt8T65IJSQp-5ug-HMMaIxkO9OdIBwRdZMGRVd_I8eCiQEhCyVEli9Xv63d7SUC_TG2teSuH3ZJmtDTjRS2GUOiqCbm0YVPriFlD_xcL4d7n5xD5obvSqE3lBTIOBWc3V_IM8Qxq0IGeQrec_diUcmMAAeJOSmvVdL05W4fv5ICTvsD7j5RB-m7CELVGVnyxGi9yBDJOG3djyvGvPZEiCKgAGeIeV6uxLCoJVk_HVzmd2jFLI_KHmyysdHQnmdzWlPB7l-Ccrgc5cm5jZ62OFX9lNTpeslXUklFUIDIZ8QGS3O1qdx1KdEWiYcuf_rgM7c9KVTVunu_hv2lU45VgVWNkN96ZULKev3OHqWy0wcJJSjwvoah6YBoL9cVKPeYVOG1Sae7WBBCVmW_5KI3mjwY6oOFjEVYhOjOgZINL1BdptKdFf1h3aC2ouiNCsMxLJDJWccIyksVvrUBgzE2u7F7ep_9Dru34UpwPg80NlrDU1htMNZKRg7g1wkArPqkmstq3VAWUP8-0t8Uarl7mQBeFDHxSKLvxZChWTot1RykORC9rT_fK4h1IqM0wbifIficrT6UeZZNBu_Q1wDikZvfEEROcmWs8OH5mGAEnkPxySvpRLAleOQ8VXI7yUMpANJmGrSkQaEE-SCwv_6ff44QL9BGt_cxnsTiLYn8e7PV_KL6UYltFiEPM8Bxiv-wZ_IubQKb0gO8S03zdCo3IqEinn03F-dLU-c=\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bQlPpjL1LpNHV0AQHJgme5Zn8kI2FwO5zxCksgAoZSKYuf920I7rhyzPs18TgDs-Czpb8vF1Gd1pLB3xq-wANZXcftvDIaF6gryUrKJqpQ2OU6CGM-YKKxhPleALunDBNLhvcp-lJVEgtGXPx2tlEpthNv-bkL47trndZV3SfQ_Advm4gbR8a4J5-1i74C__1_AHB17Yh9t2_LsPI7gYIkHf85OK7JPIMSki3Y5GyFdYsekvuCJ4eLuvCe0GDX6B5uE1uOJxNFA7NGQM1GEx7n5SJ_OLi330q3HhY5oiwevVk6AsdiHD_7QgKDCsUz3dzF4nQRugDkt2ulD__rLq37JSuDHbEpYHI599OFJyQBLYoNyEwOugYzzuLzcFpXa2VQtH4Ee27qjozkj1VDomF9oLPsuWXlGUcq5Ga7y5YTL_IJb6FPpI4Wg2L_ZRHCPiPZvfUzSGVYYC0KmjmxEK9O1yHICXMlB9dlEaHwkjFXVbL-xJNKrtuwHJVy96uJMs6ghf5SY8t_0vgVacBK_I1Z_O2LW7R3zNPqN0nH-FpwJTu9H8Ib26EqDtnPUWnllBTHopkgEWVGBbrjRMHCJ6YOQJuPjlrDZCRb9UQBj7E0XJ9q9eOG4oGFK28eBnv2174i1ELUK9g-knPFzKjUuyoX1Pby5BonPMcnxBWYCecgremMgAiHVu7BeVKTv2uYc8raGE6GaLuoywjrH-8Eio712cJ8WSHYz5rOj9pL5p6TEeWEqwyd_6eft17iLXtCjrs3ICdlMgYTkAW-ZAOgpcnFwwnoP55oGcdkdCEy7n7HPG_jeSvedfhJyo6WcIgV5fdUHlJAIm7H9mR-zw8XqC6hGTBS3ogpMFn1Iy5bWkA3JrvoACMliRa1cBTTLmVNSdc7zhpx7OJsq0yvMINvkXTSrIWy14IStrras5Y_UbmG7iphJp4mQiPLqZiggy3ILvdCDxP9qU5Tlm_-ZwFcQCIIlnFDNQezaafntnWkbGgCfj_i4t8yTn1s1DZ4N6FYWxP3LLbrXn7lVN1srRWuXUrw==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Tiffany Hamilton<br \/>AVP, Head of Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QEwLJdJMt8z_oDgTjo_nqWW2V0J1lu88UfkfgiW99Z7HFUlCtN8ktd9Gxoz_T777OkrIS4IhYxuBRfCvVmilZ_8_Wod8X_onT3XbV-91p-gH6FHieO9DERBIkaWCWKlV4R2K6OXhboENhCK7P5OWVh4_rLe9ViTsPb04vOt6_D8HCL04PrXlnx-m6lngpBu7P6StVw-hTHZpyFOFbKPhd0h6AM_M5lMmak0jZhL6e0c-_4Y0DX3aARnOu2pA4vkZ_X_hGkXEJuPPvjcredaNpZQRQxvewjWDg-Gv5zEHvfDN20lXOy-Z5kG87ST8gOP94fKAvQMw-w-X7jkvY_5b_-CULdnt52y9mtwkFqOJXmh8-Tzahce4CpRpFIZ_la8jCELgwxv1p05_rsW5x2eGbBsA-sLsFLEwB8Lzq6hGqQZMuPfQFYFengRD1HhzOEZ3XzTI6Yhb1u5AnjrmgQGD4H2U1o_2wpUWArcKHCy6BLEBvl9Gzzc9HveYCjaWf1yuHtVJb5TqKz85vVNe1eSaqviZB0x7F0vkUIrUM62Pcpkloz5S_KtGoxKKJPTgdofS\" rel=\"nofollow\" target=\"_blank\">Tiffany.Hamilton@ocugen.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2VmMjIzNmItYWExMi00MTFkLWEwYjgtYzk5NTE2ZjhjZDVkLTExOTYwNzMtMjAyNi0wMS0xMy1lbg==\/tiny\/Ocugen.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine Jay Chhablani, MD, Vitreo-Retina Specialist at the University of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926684","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine Jay Chhablani, MD, Vitreo-Retina Specialist at the University of &hellip; Continue reading &quot;Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T12:59:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data\",\"datePublished\":\"2026-01-13T12:59:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/\"},\"wordCount\":523,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/\",\"name\":\"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\",\"datePublished\":\"2026-01-13T12:59:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk","og_description":"MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine Jay Chhablani, MD, Vitreo-Retina Specialist at the University of &hellip; Continue reading \"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-13T12:59:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data","datePublished":"2026-01-13T12:59:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/"},"wordCount":523,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/","name":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=","datePublished":"2026-01-13T12:59:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDU0MyM3MzU3OTgwIzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-host-webcast-on-thursday-january-15-at-830-a-m-et-to-discuss-ocu410-phase-2-clinical-trial-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926684"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926684\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}